Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VX-985
- Development stage
- Phase 1
- Lead developer
- Vertex
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
VX-985 is an orally administered small molecule inhibitor developed as a protease inhibitor targeting the hepatitis C virus (HCV) NS3/4A serine protease. It was designed to block viral replication by inhibiting this essential viral enzyme. VX-985 was developed by Vertex Pharmaceuticals and entered early clinical development (Phase 1) for the treatment of hepatitis C infection. The drug's oral bioavailability is limited due to its tendency to form nanocolloidal complexes with bile salts, which can reduce absorption; formulation strategies such as using surfactants have been explored to improve its pharmacokinetic profile[2][3][4][5].
02
Targets
NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)
Beyond the preview
Go deeper on VX-985.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VX-985.